Arfysica Innovation

Based in Shanghai, China and founded in 2015, Shanghai Shuli Intelligent Technology Co. , Ltd, trading as Arfysica Innovation, is a company operating in non-invasive brain-computer interface (BCI) field, developing artificial intelligence multimodal brain-computer interface platforms. Its founder, Dr. Wei Wang used to be the Global Core Scientist of Siemens Healthcare.

The company owns over 500 independent intellectual property rights. In February 2026, Arfysica Innovation closed series C funding from Shanghai Daohecheng New Private Equity Fund Management, Dongfang Hengxin, Xin Ding Capital, and other investors. Arfysica Innovation provides brain-computer interface (BCI) integrated with artificial intelligence exoskeleton systems that are used to treat and improve limb movement disorders caused by central nervous system injury, consciousness and cognitive impairments, and neurodevelopmental disorders. The company's products serve departments of neurosurgery, neurology, rehabilitation, and pediatrics in multiple hospitals across China.

The company's revenue is generated by providing brain-computer interface platforms for medical treatment. The company will use the series C funding to continue to drive the generational leap in brain-computer interface technology, deepen diversified industrial applications, and build a full-chain innovation ecosystem for brain-computer interfaces covering multiple scenarios.